Join
Live feed
·
PRReleasevia Quantisnow
ACADIA Pharmaceuticals Inc. logo

Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)

ByQuantisnow·Wall Street's wire, on your screen.
ACAD· ACADIA Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACAD (ACADIA Pharmaceuticals Inc.) and more on Quantisnow.